There is a persistent assumption in mainstream medicine — and in many patient conversations — that hormone therapy is hormone therapy, that the form it takes is largely a matter of preference or convenience. A pill, a patch, a gel: same hormone, same outcome, different packaging. This assumption is clinically inaccurate, and for some women, the distinction between delivery routes is not a matter of preference at all — it is a matter of safety.
The First-Pass Problem with Oral Estrogen
When estradiol is taken orally, it undergoes what pharmacologists call first-pass hepatic metabolism. The hormone is absorbed through the gastrointestinal tract, enters the portal circulation, and passes through the liver before reaching systemic circulation. In this transit, a significant proportion of estradiol is converted to estrone — a weaker and, in high concentrations, less favorable estrogen metabolite. The result is a supraphysiologic estrone-to-estradiol ratio that does not reflect the hormonal environment the body evolved to maintain. The hepatic activation associated with oral estrogen has downstream consequences. Liver processing triggers the production of clotting factors, raises C-reactive protein (a marker of systemic inflammation), increases sex hormone-binding globulin (SHBG, which binds and inactivates free hormones), and elevates triglycerides. Critically, it activates coagulation pathways — the mechanism by which oral estrogen is associated with increased risk of venous thromboembolism (VTE) and stroke. This is not a theoretical concern. It is the finding that drove much of the skepticism around hormone therapy following the Women's Health Initiative, which used oral conjugated equine estrogen.
Transdermal Estrogen: A Different Biochemical Conversation
Transdermal estrogen — delivered via patch, gel, spray, or cream — bypasses the gastrointestinal tract and liver entirely. It enters circulation directly through the skin, achieving estradiol levels that more closely mirror the body's natural hormonal environment, without the supraphysiologic estrone conversion or hepatic activation that oral formulations produce. The clinical consequences are meaningful. Transdermal estrogen does not activate hepatic coagulation pathways in the same manner as oral estrogen, and multiple large observational studies have found no significant increase in VTE or stroke risk with transdermal delivery. The E3N cohort study — a large prospective French study of postmenopausal women — found that oral estrogen was associated with a 70 percent increased risk of VTE compared to non-use, while transdermal estrogen showed no statistically significant increase in thrombotic risk. The investigators concluded that route of estrogen administration is one of the two most important determinants of thrombotic risk in women using hormone therapy. The other is progestogen type.
Progestogen Type: Synthetic vs. Bioidentical
For women with an intact uterus, estrogen must be paired with a progestogen to protect the uterine lining from endometrial hyperplasia. But not all progestogens are equivalent — and the choice matters considerably. Synthetic progestins, particularly medroxyprogesterone acetate (MPA) used in the original Women's Health Initiative trials, have been shown to attenuate some of estrogen's cardiovascular benefits and to carry higher breast tissue proliferative activity than their bioidentical counterparts. The breast cancer signal associated with combination hormone therapy in the WHI is attributable primarily to the synthetic progestin component, not to estradiol itself. Micronized progesterone — a bioidentical molecule identical in structure to the progesterone produced by the human ovary, available as Prometrium and similar formulations — carries a more favorable safety profile. The E3N study data found no significant increase in VTE risk when transdermal estrogen was combined with micronized progesterone, compared to significant increased risk with norpregnane-derived synthetic progestins. The cardiovascular and breast tissue profiles of micronized progesterone are meaningfully different from those of synthetic progestins, and these differences should inform every prescribing conversation.
Pellet Therapy
Subcutaneous hormone pellets — small, compressed hormone pellets inserted under the skin, typically in the upper buttock — represent a third delivery approach with distinct pharmacokinetic properties. Pellets release hormones continuously at low doses over three to six months, bypassing both the gastrointestinal tract and the variability of daily application. This produces consistent serum hormone levels without the peaks that can follow oral dosing or the troughs that some women experience between patch changes. For women who struggle with absorption variability, compliance challenges, or prefer the consistency of a long-acting formulation, pellet therapy offers a clinically supported option.
Individualized Prescribing
Route selection is not a one-size-fits-all clinical decision. A woman with a personal or family history of VTE, cardiovascular risk factors, or liver disease is not an appropriate candidate for oral estrogen — regardless of whether it might otherwise be convenient. A woman with malabsorption issues may not achieve therapeutic levels through gel or cream application. A woman who has difficulty with daily adherence may achieve better clinical outcomes with a patch or pellet. Progesterone sensitivity, breast density, and prior surgical history all factor into formulation decisions. What this means in practice is that the most important conversation is not "should I take hormones?" — it is "which hormones, in which form, at which dose, by which route, at which point in my transition?" These are questions that require a provider with specific expertise in the pharmacology of hormone therapy. At Lumineux, route of delivery is individualized to your history, your laboratory findings, your lifestyle, and your risk profile. The NAMS 2022 Hormone Therapy Position Statement affirms that risks differ depending on type, dose, duration, route of administration, and timing — and that treatment should be individualized accordingly. That is not a disclaimer. It is a clinical mandate.
References
1. Canonico M, et al. "Postmenopausal Hormone Therapy and Risk of Idiopathic Venous Thromboembolism." Arteriosclerosis, Thrombosis, and Vascular Biology, 2010. https://www.ahajournals.org/doi/10.1161/atvbaha.109.196022
2. The North American Menopause Society. "The 2022 Hormone Therapy Position Statement of The Menopause Society." Menopause, 2022. https://pubmed.ncbi.nlm.nih.gov/35797481/
3. BC PharmaCare Plan NP. "Menopausal Hormone Therapy Benefit List." March 2026. https://www2.gov.bc.ca/gov/content/health/practitioner-professional-resources/pharmacare/plans/national-pharmacare-plan-np/plan-np-menopausal-hormone-therapy